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Background: The effectiveness of current treatment recommendations for vitamin D insufficiency in children with CF is unknown. Therefore, we
assessed the effectiveness of vitamin D2 50,000 IU once daily for 28 days for vitamin D insufficiency.
Methods: Retrospective chart review of pediatric CF patients from 2006–2008. Vitamin D2 50,000 IU daily for 28 days was given to patients with
25-OHD b30 ng/mL and repeat 25-OHD levels were obtained after completion of therapy.
Results: One hundred forty-seven levels from 97 individuals were assessed. Success of treatment was 54% (n=80/147). Seventeen of 39 patients
(43%) followed for an additional 6–18 months were able to maintain levels of ≥30 ng/mL.
Conclusions: Vitamin D2 50,000 IU daily for 28 days was effective in correcting vitamin D insufficiency in approximately 50% of subjects.
However, almost half of successfully treated patients were unable to maintain normal 25-OHD levels N6 months after completion of therapy,
implying that this effect is transient.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Vitamin D; Bone health1. Introduction
Vitamin D insufficiency has been a wide-spread problem in
pediatric patients and is becoming increasingly more common
in the United States. Nutritional rickets has been shown to be on
the rise in otherwise healthy children between the years 1986
and 2003 [1] and outbreaks have been reported throughout theAbbreviations: CF, cystic fibrosis; 25-OHD, 25-hydroxy-vitamin D; IU,
international units; PTH, parathyroid hormone; FEV1, forced expiratory volume
in 1 s; BMI, body mass index; χ2, chi-square; 25-OHD2, 25-hydroxy-vitamin
D2; 25-OHD3, 25-hydroxy-vitamin D3; UV, ultraviolet.
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1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.01.002United States [2,3]. Hypovitaminosis D without nutritional
rickets is also on the rise in pediatric populations. This has led
the American Academy of Pediatrics (AAP) and the Pediatric
Endocrine Society to make recommendations for an increase in
the daily intake of vitamin D from 200 IU/day to 400 IU/day in
otherwise healthy children [4,5]. Vitamin D insufficiency is
even more prevalent in susceptible patient populations, such as
patients with cystic fibrosis (CF). Multiple groups have shown
that pediatric patients with CF often have vitamin D
insufficiency [6–8]. These studies demonstrate the difficulty
that patients have maintaining the recommended 25-hydroxy-
vitamin D (25-OHD) level of 30 ng/mL set out by the US CF
Foundation consensus panel on CF-related bone disease [9].
In 2002, this panel made recommendations on replenishment
of vitamin D when 25-OHD levels are less than 30 ng/mL [9].
Daily requirements were set at 400 IU/day of vitamin D2 for
patients b1 year old and 800 IU/day for older children and
adults. These recommendations are twice of that currently
recommended by the AAP for healthy children. They furtherd by Elsevier B.V. All rights reserved.
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8 weeks for children≥5 years and 12,000 IU once per week for
8 weeks for children b5 years in those found to be insufficient
(defined as a 25-OHD level b30 ng/mL). Levels were then to be
rechecked and if remaining b30 ng/mL, patients were to be
treated with vitamin D2 50,000 IU twice a week for 8 weeks.
Boyle et al. [10] showed that in adult patients these repletion
doses of vitamin D2 did not achieve the desired result of a 25-
OHD level ≥30 ng/mL. Our pediatric group published data on
these repletion recommendations and also found that the
recommended treatment doses do not successfully treat the
majority of patients with vitamin D insufficiency [11].
Therefore, our clinic has been treating patients with vitamin D
insufficiency with vitamin D2 50,000 IU once a day for 28 days
for the past 2 years. Thus, we undertook the current study to
determine the effectiveness of this treatment strategy in
pediatric patients with CF who are vitamin D insufficient.2. Subjects and methods
2.1. Population
This quality improvement study was approved by the Johns
Hopkins Institutional Review Board. A retrospective chart
review of pediatric patients (b21 years) routinely followed at
the Johns Hopkins Pediatric CF center from January 2006
through December 2008 was performed. Data abstracted
included: age, gender, exocrine pancreatic status, 25-OHD
levels, body mass index (BMI) expressed as a percentile, and
forced expiratory volume in 1s (FEV1) expressed as percent
predicted. The patients were confirmed to have CF by sweat test
and/or genotyping.2.2. Routine vitamin D supplementation and monitoring
All CF patients were given daily multivitamins with fat
soluble vitamins A, D, E and K regardless of 25-OHD levels
according to the routine CF treatment guidelines [9]. The
amount of vitamin D in the daily supplementation ranged from
400 to 800 IU daily based on the patient's age. Patients were
seen on a quarterly basis for routine care and during these visits,
weight, height, and BMI percentile for age were obtained for
patients ≥2 years. In addition, pulmonary function testing was
performed in all children ≥5 years. Blood was obtained at least
once a year to measure 25-OHD levels and more frequently if
patients were given repletion therapy with vitamin D2.
Prevalence rates were calculated using only the first level
obtained for a subject so that all subjects, whether insufficient or
sufficient were captured in a given year. All 25-OHD levels
reported were performed by Quest Diagnostics (Chantilly, VA)
using liquid chromatography–tandem mass spectroscopy.
During the study period, there were reports of inaccurate 25-
OHD levels obtained by Quest Diagnostics [12]; however, the
facility in Chantilly, VA was not one of the facilities affected
(Quest Diagnostics, personal communication).2.3. Treatment of vitamin D insufficiency
Starting in May 2006 through September 2008, our strategy
for treating patients with 25-OHD levels b30 ng/mL was to
prescribe vitamin D2 50,000 IU once a day for 28 days. All
patients were instructed to obtain follow-up 25-OHD levels 2–
4 weeks after the completion of treatment and all follow-up
levels were obtained a minimum of 2 weeks from end of
treatment. If patients continued to have 25-OHD levels b30 ng/
mL upon reevaluation, another course of vitamin D2 50,000 IU
once a day for 28 days was prescribed.
Patients were included in this analysis if they were treated
with vitamin D2 50,000 IU once a day for 28 days during the
time studied. Analysis was performed based on having a
treatment course, not on an individual patient basis. Thus some
patients were included more than once if they were given
multiple treatments during the 2 years studied. Patients were
excluded from analysis if no follow-up level was available after
a treatment course was prescribed; if 25-OHD follow-up levels
were obtained more than 1 year after the pre-treatment level was
obtained; or if follow-up occurred after December 31, 2008.
2.4. Statistical analysis
Demographic characteristics were tested for differences
using the Student's t-test. Logistic regression was used to
determine if pre-treatment level predicted post-treatment
outcome. Subgrouping of 25-OHD levels was also done to
determine if there was a response to treatment based on initial
25-OHD levels and evaluated using chi-square (χ2) tests.
Seasonal effect was assessed using χ2 tests. Difference in
response divided into 25-OHD-vitamin D2 and vitamin D3
levels was assessed using two-sided Wilcoxon signed-rank test.
Analysis was performed using STATA version 10 (Statacorp
LP, College Station, TX). Statistical significance was set as a
p value b0.05 and all reported p values are two-sided.
3. Results
3.1. Demographics and prevalence of vitamin D insufficiency
A total of 244 treatments with vitamin D2 50,000 IU once a
day occurred between January 2006 and December 2008.
During this period, the prevalence (calculated using the first 25-
OHD level obtained in a given year for a subject) of vitamin D
insufficiency in our clinic was 46.2% (n=96/208) in 2006,
46.8% (94/201) in 2007 and 54.6% (99/181) in 2008. Of the
244 treatment courses given, 28 were excluded because no
further follow-up was available. Thirty-one were excluded
because pre or post-treatment testing occurred at a lab other than
Quest Diagnostics. Eighteen were excluded because follow-up
occurred after December 31, 2008 and another 20 were
excluded because follow-up occurred more than 1 year from
the pre-treatment level. This left 147 treatment courses for
evaluation obtained from 97 different individuals. Sixty-one
individuals were only given one treatment course; 24 were
given 2 courses; 11 were given 3 courses; and 1 person was
Table 1
Clinical characteristics for patients at the time the pre-treatment 25-OHD level was obtained. a
Total Successfully treated Not successfully treated p value
Number of patients 97 52 45
Male gender, N (% of group) 50 (51.5%) 28 (46.7) 21 (53.8) 0.486
Pancreatic insufficient, N (% of group) 88 (90.7%) 47 (90.4) 41 (91.1) 0.903
Caucasian ethnicity, N (% of group) 83 (85.6%) 44 (84.6) 39 (86.6) 0.777
Age (years), mean±SD 10.9±5.2 10.7±5.6 11.2±4.8 0.638
BMI for children ≥2 y/o, percentile for age (n=92), mean±SD 43.6±27.6 44.8±26.6 40.8±28.8 0.490
FEV1, % predicted (n=77), mean±SD 79.6±25.7 85.0±24.4 74.3±25.9 0.070
Abbreviations: BMI=body mass index, FEV1=forced expiratory volume in 1 s.
a For patients who were given more than one round of vitamin D2 50,000 IU for 28 days, only the clinical information for the first treatment course is reported.
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patients at the time of the first pre-treatment 25-OHD level
obtained are presented in Table 1. Patients ranged in age from
8 months to 20 years and 51.5% were male. The majority of
patients were pancreatic insufficient (90.7%) and the mean BMI
for children ≥2 years was less than the 50th percentile for age.
There were no significant differences in demographics for those
subjects who were successfully treated and those who were not
(Table 1).
3.2. Success of vitamin D2 treatment for vitamin D insufficiency
The median time from pre-treatment 25-OHD level to post-
treatment was 140 days (range 42–364 days). The success rate
of vitamin D2 50,000 IU daily for 28 days, defined as a repeat
25-OHD level ≥30 ng/mL, was 54.4% (n=80/147). Overall,
the median pre-treatment 25-OHD level was 24 ng/mL (range
5–29) and significantly increased to 33 ng/mL (range 5–310)
(signed-rank p value b0.001) (Fig. 1). Thirty-three patients had
a decline in 25-OHD levels, 2 remained the same and 12
patients had levels N80 ng/mL post-treatment. By logistic
regression, for every 1 ng/mL increase in baseline 25-OHD
level subjects had a 0.07 increased odds of becoming vitamin DFig. 1. Pre- and post-treatment 25-OHD levels by season. Overall pre-treatment and p
the range of values. Winter is defined as January–March, spring as April–June, sumsufficient (25-OHD level ≥30 ng/mL) after treatment
(p=0.049; 95% CI: 1.00, 1.13). However, when subjects were
dichotomized by pre-treatment level into subgroups of 0–19 ng/
mL (n=40) and 20–29 ng/mL (n=107), there was no statistical
difference in response based on initial category (p=0.51).
Additionally, there was no statistical difference between
patients who developed post-treatment 25-OHD levels
N80 ng/mL and those who had lower levels based on which
pre-treatment group they were in (p=0.24).
Since it is likely that a delay in obtaining the post-treatment
level affected our results, we performed analysis on only those
treatment courses which had a follow-up level obtained within
6 months and within 3 months, respectively of the pre-treatment
level. Ninety-two follow-up levels were obtained within
6 months of the pre-treatment level. Of these, 61 (66.3%)
were vitamin D sufficient after the course of vitamin D2.
Furthermore, there were 55 treatment courses in which follow-
up occurred within 3 months and of these 41 (74.5%) were
vitamin D sufficient after the course of vitamin D2. All 12 post-
treatment 25-OHD levels N80 ng/mL were obtained from
subjects who had follow-up within 3 months of the pre-
treatment level. Linear regression of all 147 treatment courses
shows that for every one day increase in time to post-treatmentost-treatment values are presented with a median value and the high and low of
mer as July–September and fall as October–December.
Fig. 2. Change in post-treatment level from pre-treatment by time to follow-up.
One hundred forty-seven treatment values are presented as the difference in
post-treatment level from pre-treatment level according to the number of days
until follow-up level was obtained. The shortest time of follow-up was 42 days
as this represents 2 weeks after completion of the 28 days of treatment. The line
represents the line of regression for the values.
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decreases by 0.08 (pb0.001) (Fig. 2). Thus a delay in obtaining
repeat levels did affect the assessment of successful treatment of
vitamin D insufficiency.
3.3. Seasonal effect on treatment
Season also affected the success of treatment. A higher
success rate was seen in those patients who had pre-treatmentFig. 3. Pre- and post-treatment levels separated by total 25-hydroxy-vitamin D (25-OH
obtained values. Pre-treatment total 25-OHD levels ranged from 6–29 ng/mL with a m
mL with a median of 33 ng/mL. Pre-treatment 25-OHD2 had a median of 4 ng/mL (lo
levels had a median of 12 ng/mL with a range of 4 to 97 ng/mL. Pre-treatment 25-O
treatment 25-OHD3 levels with a median of 15 ng/mL and a range of 4–49 ng/mL. P
scaling purposes, one outlier who had a post-treatment 25-OHD level of 175 ng/mLlevels obtained in winter (n=33/54) or spring (n=32/51) com-
pared with summer (n=11/31) or fall (n=4/11) (χ2 p=0.04).
Fig. 1 shows the median and range of the pre- and post-
treatment 25-OHD levels segmented based on the season in
which the original 25-OHD level was drawn.
3.4. Evaluation of 25-OH-vitamin D2 and 25-OH-vitamin D3
Since there was a season effect on 25-OHD levels, we
wished to assess whether the success of this treatment strategy
was due to the treatment itself or exposure to sunlight in the
different seasons. As of September 2006, 25-OHD levels were
separated into 25-hydroxy-vitamin D2 (25-OHD2) and 25-
hydroxy-vitamin D3 (25-OHD3) levels providing for an analysis
of this issue. One hundred eleven of the 147 treatment courses
had 25-OHD levels reported as 25-OHD2 and 25-OHD3 and the
limit of detection for 25-OHD2 or 25-OHD3 levels was 4 ng/mL.
Of these 111 treatment courses, 62 (55.8%) were successfully
treated. Sixty-eight were noted to have pre-treatment 25-OHD2
of 4 ng/mL and the remainder ranged from 5–19 ng/mL. Post-
treatment 25-OHD2 median level was 12 ng/mL (range 4–168;
with 33 values of 4 ng/mL) (Fig. 3). The median pre-treatment
25-OHD3 level was 19 ng/mL (range 4–29; with 1 level of 4 ng/
mL) and the post-treatment median was 15 ng/mL (range 4–49;
with 3 levels of 4 ng/mL) (Fig. 3).
The majority of 25-OHD2 levels increased from pre-
treatment to post-treatment whereas the majority of 25-OHD3
levels actually decreased. The change (difference in pre-
treatment to post-treatment) in 25-OHD2 levels was signifi-
cantly different from the change in 25-OHD3 levels (Student'sD) level, 25-OHD2, and 25-OHD3 assayed using liquid chromatography in 110
edian of 25 ng/mL. Post-treatment total 25-OHD levels ranged from 5–102 ng/
wer limit of the test) with a range of 4 to 19 ng/mL and post-treatment 25-OHD2
HD3 levels had a median of 20 ng/mL with a range of 4–29 ng/mL and post-
lease note that the labeled bar represents the median values for the patients. For
was removed.
Fig. 4. Box plot of the change in pre-treatment and post-treatment levels for total 25-hydroxy-vitamin D (25-OHD), 25-OHD2 and 25-OHD3 by season. The difference
in post-treatment levels from pre-treatment level for 110 obtained values who had total 25-OHD levels separated into 25-OHD2 and 25-OHD3 levels is shown with the
median and interquartile range depicted. One outlier with a change in total 25-OHD of N100 ng/mL was removed. Winter is defined as January–March, spring as
April–June, summer as July–September and fall as October–December.
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OHD2 remained significantly different from the change in 25-
OHD3 levels for all seasons except fall. For winter the 25-OHD2
level increased by 12.2±2.7 ng/mL (mean±standard error of
the mean) whereas 25-OHD3 decreased by 0.1±1.5 ng/mL
(p=0.002). In the spring, 25-OHD2 increased by 16.9±4.0 ng/
mL and 25-OHD3 increased by 0.1±1.6 ng/mL (p=0.002).
Summer had the greatest change in 25-OHD2 levels with an
increase of 22.1±9.6 ng/mL and 25-OHD3 decreased by 7.4±
2.0 ng/mL (p=0.008). However in the fall, 25-OHD2 increased
by only 9.9±3.9 ng/mL and 25-OHD3 decreased by 3.1±
2.7 ng/mL (p=0.057) (Fig. 4). These data demonstrate that the
increase in 25-OHD levels was due to an increase in 25-OHD2
rather than in 25-OHD3, and support the use of vitamin D2
rather than sunlight exposure as an explanation for the increase
in 25-OHD levels in our population.
3.5. Long-term follow-up
Additional follow-up 25-OHD levels were available in 39
individuals (not treatment courses) after the initial follow-up
was obtained. These 25-OHD levels were obtained more than
6 months but less than 18 months after the post-treatment level.
Of these 39 individuals, 27 were vitamin D sufficient on the
initial post-treatment level. Of these 27 individuals, 13 (48%)
were insufficient when the 25-OHD level was obtained 6–
18 months after the post-treatment level. Furthermore, of the 12
who had remained insufficient at the post-treatment level, 4
(33%) remained insufficient when checked 6–18 months later.
4. Discussion
To our knowledge, this is the first study assessing the use of
vitamin D2 50,000 IU daily for 28 days as a treatment regimenfor vitamin D insufficiency in pediatric patients with CF. This
treatment was more effective than our previously reported
treatment strategies of vitamin D2 50,000 IU once, twice or
thrice a week for 8 weeks [11]. However, the current approach
was still only successful in treating vitamin D insufficiency in
approximately 50% of the patients with low 25-OHD levels.
Furthermore, almost half of the successfully treated patients had
recurrence of vitamin D insufficiency 6–18 months after com-
pletion of this intermittent regimen. These results show that
patients are unable to maintain the 25-OHD goal of≥30 ng/mL
set by the CF Foundation using the currently recommended
daily intake dose with intermittent vitamin D2 for vitamin D
insufficiency. This supports the idea that once successfully
treated patients need to change their daily dose in order to
maintain vitamin D sufficiency as opposed to being provided
with intermittent therapy.
Vitamin D insufficiency is increasingly recognized as a
common problem in pediatric patients [13–15] and this has led
to a change in the daily recommended intake of vitamin D to
400 IU/day. This problem is concerning as multiple reports
have linked vitamin D deficiency to cardiovascular events,
type I diabetes and cancer [16]. There have also been reports of
vitamin D deficiency showing an association with development
of asthma [17] as well as increased frequency of viral illnesses
[18]. This problem is especially concerning in children with CF
as vitamin D insufficiency is likely related to osteopenia and
bone disease which develops in adult CF patients. Additionally
vitamin D insufficiency has been associated with decreased
lung function in adults with CF [19]. Multiple clinics have
reported a prevalence of vitamin D insufficiency as high as
50%–60% in their patients [6,8,10,11,19–21]. This observation
is despite routine daily intake of 400 IU to 1000 IU of vitamin D
[6–8,11,19,20]. In this report we confirm these observations as
all of our subjects were routinely receiving at least 400 IU of
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the form of multivitamins with vitamins A, D, E, and K. We
then supplemented those patients who were vitamin D
insufficient intermittently with 50,000 IU of vitamin D2 daily
for 28 days. The present study confirms the data that daily
vitamin D supplements, in the form of multivitamins, which we
are providing to our patients are not adequate to prevent vitamin
D insufficiency. Furthermore, although intermittent treatment
may transiently correct vitamin D insufficiency this effect is not
likely to be sustained for long periods of time once subjects
return to the regularly prescribed daily vitamins.
Since multiple studies have demonstrated a high prevalence
of vitamin D insufficiency, various repletion strategies are being
studied in an attempt to find the appropriate repletion and
maintenance strategy for vitamin D deficiency in CF patients
[22–25]. One option which is gaining support is to use vitamin
D3 (cholecalciferol) instead of vitamin D2 (ergocalciferol) in
repletion regimens since vitamin D3 may be more effective
[26,27]. Both Armas et al. [26] and Trang et al. [27] found that
50,000 IU of vitamin D3 maintained 25-OHD levels for a longer
period of time than 50,000 IU of vitamin D2 in normal subjects
when given either as a single dose or for 14 days, respectively.
However, Holick et al. [28] found that vitamin D3 and vitamin
D2 were equally effective when given for a longer time course
(11 weeks) to normal subjects. A recent study comparing these
vitamin D formulations as well as UV light has been undertaken
in CF patients [22]. Although both vitamin D3 and vitamin D2
increased 25-OHD levels, vitamin D3 was found to increase
levels more significantly. This result seems promising as
another study has shown that vitamin D3 is effective in
increasing vitamin D levels [29]. Stephenson et al. [29] have
shown that vitamin D3 given daily in doses of 400 to N1000 IU
to an adult CF population was effective in raising vitamin D
levels in 92% of subjects and in 17% of patients to levels
N75 nmol/mL (N30 ng/mL). However, there was no assessment
of whether higher doses were more effective than the lower
doses so it is unclear what the optimal daily dose of vitamin D3
should be. Another option to treat vitamin D insufficiency is the
use of UV light. Khazai et al. [22] compared UV light to vitamin
D2 and vitamin D3 therapy in CF patients. UV light did not
provide a significant increase in 25-OHD levels, although this
may have been due to non-compliance. Other studies have
shown a response to UV-B exposure in CF populations [24,30].
Long-term data is not available on any of these regimens.
However, it seems doubtful that any intermittent strategy would
be as effective as an increase in daily supplementation or daily
exposure to UV light. Based on our results and those of others
we have changed the vitamin D supplementation regimen
employed by our pediatric patients. We currently recommend
1000 IU of vitamin D3 in addition to the daily recommended
multivitamins with vitamins A, D, E and K provided to each of
our patients. It is too early to know if this therapy is more
effective than our previous approaches.
We must acknowledge several limitations in this study. The
first is that we did not collect data on toxicity with use of this
therapy. The exact 25-OHD level associated with toxicity is not
known. The upper limit for vitamin D intake was studied in the1930s but these studies were based on small numbers [31,32].
An epidemic of hypercalcemia in England in 1960 was
attributed to supplementation with 2000–4000 IU/day of
vitamin D [33]. These studies established the upper intake
limit of 2000–4000 IU and repeated upper limit testing has not
been recommended [34]. Unfortunately, these studies of
hypervitaminosis D did not utilize 25-OHD levels, so the 25-
OHD level corresponding to hypervitaminosis is not known. In
the current study, 12% of our patients had a 25-OHD level
greater than 80 ng/mL. Since our study was retrospective it is
very difficult for us to determine if patients had toxicity from the
high-dose ergocalciferol treatment. We did not collect data on
calcium levels at the time of follow-up 25-OHD levels. Other
side effects such as anorexia, weight loss and lethargy are
common complaints in CF and thus it would be very difficult for
clinicians to determine if patients are experiencing a medication
side effect or a complication of CF. Therefore, it would be
prudent to monitor calcium levels when treating patients with
high-dose vitamin D.
Further limitations of this study are that it was a retrospective
study and not a randomized controlled trial. We did not control
for when patients started medications or when repeat 25-OHD
levels were obtained. Patients were typically mailed prescrip-
tions and took the medications unobserved. Adherence to
treatment was monitored by asking if patients had completed
therapy prior to obtaining a follow-up 25-OHD level. By this
simple intervention subjects may have become more compliant
with their routine therapies such as use of vitamins A, D, E, and
K which may confound the improvement in 25-OHD seen in
this study. Another limitation to this study is that we based our
treatment strategy on our observation that strategies involving
lower doses of vitamin D2 did not improve 25-OHD levels in a
majority of CF patients [11]. As already described, the current
daily vitamin D recommendations from the CF Foundation may
not be appropriate for pediatric patients with CF and this alone
may be the reason for continued diminished response to any
repletion strategy. Furthermore the CF Foundation recommen-
dations were for use of ergocalciferol due to ease of
administration. However, based on the data from Armas et al.
[26] vitamin D2 has a shorter half-life than vitamin D3. After a
single dose of vitamin D2 50,000 IU by day fourteen 25-OHD
levels were back to baseline whereas for vitamin D3 25-OHD
levels remained greater than baseline for more than 28 days.
Thus any intermittent repletion strategy that stops the use of
vitamin D2 will likely not be sustainable. Finally, our study was
not a long-term longitudinal study since only a few subjects had
additional follow-up 6–18 months after treatment completion.
Research on vitamin D insufficiency would greatly benefit from
a prolonged, longitudinal study to evaluate the effectiveness of
intermittent treatment regimens versus an increase in daily
supplementation with vitamins D2 or D3. This would be
especially beneficial in patients with CF where non-compliance
with daily regimens is frequently encountered.
In conclusion, this study demonstrates that vitamin D2 given
as 50,000 IU once daily for 28 days was effective in treating
vitamin D insufficiency in approximately 50% of patients.
However, this improvement appears to be transient since almost
149D.M. Green et al. / Journal of Cystic Fibrosis 9 (2010) 143–149half of the successfully treated patients were found to have
recurrence of vitamin D insufficiency upon further follow-up.
Thus a treatment regimen which increases the daily intake of
vitamin D may be more appropriate than an intermittent treat-
ment strategy.
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